KDM7A

Lysine-specific demethylase 7A · Q6ZMT4 · KDM7A on Sugi Atlas →

4,577 patent compounds predicted against KDM7A, 3,208 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Iodide (SCHEMBL3454617)	0.32	4/20
Amiodarone (SCHEMBL16284)	1.00	2/20
Amiodarone (SCHEMBL41348)	0.98	2/20
Amiodarone (SCHEMBL1648547)	0.96	2/20
Desethylamiodarone (SCHEMBL4535165)	0.74	2/20
Hydrochloric Acid (SCHEMBL3212507)	0.73	2/20
SCHEMBL3228984	0.73	2/20
Budiodarone (SCHEMBL1946426)	0.70	2/20
Budiodarone (SCHEMBL1946428)	0.70	2/20
Budiodarone (SCHEMBL3123242)	0.70	2/20
SCHEMBL4588327	0.68	2/20
Amiodarone (SCHEMBL3134442)	0.67	2/20
Amiodarone (SCHEMBL297474)	0.63	2/20
SCHEMBL3223737	0.62	2/20
SCHEMBL3128930	0.60	2/20
SCHEMBL3128944	0.60	2/20
SCHEMBL3128785	0.59	2/20
SCHEMBL3128794	0.59	2/20
Etabenzarone (SCHEMBL2108676)	0.58	2/20
SCHEMBL4588409	0.57	2/20

Clinical trials — most relevant to KDM7A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Can We Achieve 'high-quality' Weight Loss Through Supplementation and Exercise? the TRIM MUSCLE Study	PHASE3	COMPLETED
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome	PHASE2	ACTIVE_NOT_RECRUITING
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome	PHASE2	ACTIVE_NOT_RECRUITING
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes	PHASE1/PHASE2	COMPLETED
Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2	PHASE2	ACTIVE_NOT_RECRUITING
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors	PHASE1	RECRUITING
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma	PHASE1	RECRUITING
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma	PHASE1	UNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Model to Predict pCR and IrAEs in Early Stage Non-small Cell Lung Cancer	nan	UNKNOWN
The Danish TURNER Cryopreservation Study	nan	RECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Expression of TET1 Gene in Acute Leukaemia	nan	UNKNOWN
Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia	nan	UNKNOWN
The Crosstalk Between the Epigenome and Mitochondria in SCI	nan	NOT_YET_RECRUITING
The Molecular Pathogenesis Study of Cataract	nan	UNKNOWN
Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19	nan	COMPLETED
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders	nan	COMPLETED
MIF Involvement in AML	nan	ACTIVE_NOT_RECRUITING
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer	nan	UNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
Mechanisms of Immune Deficiency	nan	UNKNOWN
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors	nan	UNKNOWN
X-chromosome Inactivation, Epigenetics and the Transcriptome	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a KDM7A binder may also engage these)

Protein	Name	Similarity
Q3UWM4	—	1.000	Q3UWM4 →
Q5RHD1	—	0.999	Q5RHD1 →
Q80TJ7	—	0.998	Q80TJ7 →
Q08D35	—	0.994	Q08D35 →
P79457	—	0.992	P79457 →
Q62315	—	0.992	Q62315 →
P0CH95	—	0.991	P0CH95 →
Q498F0	—	0.991	Q498F0 →
Q5QJC2	—	0.990	Q5QJC2 →
KAT2A	Histone acetyltransferase KAT2A	0.989	landscape →
Q9R037	—	0.989	Q9R037 →
Q5F363	—	0.989	Q5F363 →
Q92833	—	0.989	Q92833 →
Q9XSC3	—	0.989	Q9XSC3 →
NSD3	Histone-lysine N-methyltransferase NSD3	0.988	landscape →
Q6NVE8	—	0.988	Q6NVE8 →
Q64127	—	0.988	Q64127 →
KAT2B	Histone acetyltransferase KAT2B	0.988	landscape →
Q3UG20	—	0.988	Q3UG20 →
Q9H694	—	0.988	Q9H694 →
Q9XSW2	—	0.987	Q9XSW2 →
Q9EQM6	—	0.987	Q9EQM6 →
Q6IE81	—	0.987	Q6IE81 →
Q5HYC2	—	0.987	Q5HYC2 →
PHF8	Histone lysine demethylase PHF8	0.987	landscape →
Q9HBD1	—	0.987	Q9HBD1 →
Q3UQU0	—	0.987	Q3UQU0 →
Q6GQL0	—	0.987	Q6GQL0 →
Q02395	—	0.987	Q02395 →
Q6GQJ2	—	0.986	Q6GQJ2 →